Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: RTN022
MIFTS: 54

Retinal Vein Occlusion

Categories: Blood diseases, Cardiovascular diseases, Eye diseases, Neuronal diseases, Rare diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Retinal Vein Occlusion

About this section

MalaCards integrated aliases for Retinal Vein Occlusion:

Name: Retinal Vein Occlusion 12 54 44 15 37 17 71
Occlusion, of Retinal Vein 12

Classifications:

MalaCards categories:
Global: Rare diseases
Anatomical: Cardiovascular diseases Neuronal diseases Eye diseases Blood diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:1727
MeSH 44 D012170
NCIt 50 C34981
SNOMED-CT 67 46085004
UMLS 71 C0035328
Sources

Summaries for Retinal Vein Occlusion

About this section
MalaCards based summary : Retinal Vein Occlusion, also known as occlusion, of retinal vein, is related to central retinal vein occlusion and retinal ischemia. An important gene associated with Retinal Vein Occlusion is VEGFA (Vascular Endothelial Growth Factor A), and among its related pathways/superpathways are ERK Signaling and PEDF Induced Signaling. The drugs Bevacizumab and Dipivefrin have been mentioned in the context of this disorder. Affiliated tissues include endothelial, eye and retina, and related phenotypes are cardiovascular system and homeostasis/metabolism

Sources

Related Diseases for Retinal Vein Occlusion

About this section

Diseases in the Retinal Vein Occlusion family:

Central Retinal Vein Occlusion

Diseases related to Retinal Vein Occlusion via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 947)
# Related Disease Score Top Affiliating Genes
1 central retinal vein occlusion 32.1 VEGFA SERPINF1 SERPINC1 MTHFR LOXL1 IL6
2 retinal ischemia 31.7 VEGFA TNF CXCL12
3 neovascular glaucoma 31.5 VEGFA KDR CXCL8
4 vasculitis 31.4 TNF IL6 CCL2 APOH
5 branch retinal artery occlusion 31.3 VEGFA SERPINC1 MTHFR F2 APOH
6 diabetic macular edema 31.2 VEGFA SERPINF1 IL6 CCL2
7 homocysteinemia 31.1 SERPINE1 SERPINC1 MTHFR F5 F2 CCL2
8 retinal vasculitis 31.0 TNF CCL2 APOH ACE
9 lipid metabolism disorder 31.0 SERPINE1 IL6 CCL2 ACE
10 thrombophilia 31.0 SERPINE1 SERPINC1 MTHFR F5 F3 F2
11 macular retinal edema 30.9 VEGFA TNF SERPINF1 KDR IL6 IL1B
12 intraocular pressure quantitative trait locus 30.9 VEGFA SERPINF1 LOXL1 EDN1
13 endophthalmitis 30.9 VEGFA TNF IL6 IL1B CXCL8
14 panuveitis 30.7 TNF IL6 ACE
15 macular holes 30.7 VEGFA SERPINF1 IL6 CXCL8 CCL2 ANGPT2
16 sarcoidosis 1 30.7 TNF IL1B CCL2 ACE
17 thrombophilia due to activated protein c resistance 30.6 SERPINE1 SERPINC1 MTHFR F5 F3 F2
18 thrombotic thrombocytopenic purpura 30.6 SERPINC1 F3 APOH
19 factor xii deficiency 30.6 SERPINC1 F5 F3 APOH
20 uveitis 30.6 TNF SERPINF1 IL6 IL1B CXCL8 CCL2
21 protein s deficiency 30.6 SERPINC1 MTHFR F5 F3 F2 APOH
22 central retinal artery occlusion 30.6 VEGFA SERPINC1 MTHFR F2 EDN1
23 conjunctivitis 30.6 TNF IL6 CXCL8 CCL2
24 brucellosis 30.6 TNF IL6 CXCL8
25 arteritic anterior ischemic optic neuropathy 30.5 MTHFR F5 F2 ACE
26 posterior scleritis 30.5 VEGFA TNF ACE
27 toxoplasmosis 30.5 TNF IL6 IL1B F2
28 amaurosis fugax 30.5 SERPINE1 MTHFR F5
29 cryoglobulinemia 30.5 TNF IL6 IL1B
30 microvascular complications of diabetes 5 30.5 VEGFA SERPINF1 SERPINE1 KDR CXCL12 ANGPT2
31 chorioretinitis 30.5 VEGFA TNF IL6 IL1B ACE
32 sticky platelet syndrome 30.5 SERPINE1 SERPINC1 F5
33 cataract 30.4 VEGFA TNF SERPINF1 MTHFR LOXL1 IL6
34 transient cerebral ischemia 30.4 MTHFR IL1B CCL2 APOH
35 hypopyon 30.4 VEGFA TNF IL6 IL1B
36 ulcerative colitis 30.4 TNF IL6 IL1B CXCL8
37 antiphospholipid syndrome 30.4 TNF SERPINE1 SERPINC1 MTHFR F5 F3
38 celiac disease 1 30.4 TNF IL6 IL1B CXCL8
39 iritis 30.4 VEGFA TNF IL6 ACE
40 thrombosis 30.4 SERPINE1 SERPINC1 MTHFR F5 F3 F2
41 carotid artery occlusion 30.4 IL1B F5 APOH
42 churg-strauss syndrome 30.4 TNF IL1B CXCL8
43 carotid stenosis 30.4 VEGFA TNF MTHFR CXCL8 ACE
44 prothrombin deficiency, congenital 30.3 SERPINC1 F5 F2 APOH
45 anterior scleritis 30.3 TNF ACE
46 sneddon syndrome 30.3 SERPINC1 F5 F2 APOH
47 cavernous sinus thrombosis 30.3 SERPINC1 F3 F2
48 peptic ulcer disease 30.3 TNF IL1B CXCL8
49 severe pre-eclampsia 30.3 VEGFA SERPINC1 F5 APOH
50 papillary conjunctivitis 30.3 IL6 CXCL8 CCL2

Graphical network of the top 20 diseases related to Retinal Vein Occlusion:



Diseases related to Retinal Vein Occlusion
Sources

Symptoms & Phenotypes for Retinal Vein Occlusion

About this section

MGI Mouse Phenotypes related to Retinal Vein Occlusion:

46 (show all 17)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.47 ACE ANGPT2 CXCL12 EDN1 F2 F3
2 homeostasis/metabolism MP:0005376 10.44 ACE ANGPT2 APOH EDN1 F2 F3
3 growth/size/body region MP:0005378 10.38 ACE EDN1 F2 F3 F5 IL1B
4 immune system MP:0005387 10.34 ACE ANGPT2 CCL2 CXCL12 F2 F3
5 mortality/aging MP:0010768 10.34 ACE ANGPT2 APOH CXCL12 EDN1 F2
6 hematopoietic system MP:0005397 10.3 ACE ANGPT2 CXCL12 F3 IL1B IL6
7 integument MP:0010771 10.26 ANGPT2 F2 F3 F5 IL1B IL6
8 embryo MP:0005380 10.2 ACE EDN1 F2 F3 F5 KDR
9 nervous system MP:0003631 10.2 ACE CXCL12 EDN1 F2 F3 F5
10 digestive/alimentary MP:0005381 10.16 ANGPT2 EDN1 F2 IL6 LOXL1 SERPINF1
11 liver/biliary system MP:0005370 10.16 ACE CXCL12 F5 IL6 KDR MTHFR
12 muscle MP:0005369 10.06 CXCL12 EDN1 F2 F3 IL6 KDR
13 reproductive system MP:0005389 10 ACE ANGPT2 CXCL12 F2 IL6 LOXL1
14 neoplasm MP:0002006 9.91 ACE F3 IL1B IL6 SERPINE1 TNF
15 respiratory system MP:0005388 9.81 ANGPT2 F2 F3 IL6 KDR LOXL1
16 skeleton MP:0005390 9.65 EDN1 F2 IL1B IL6 KDR MTHFR
17 vision/eye MP:0005391 9.36 ACE ANGPT2 F3 IL6 KDR LOXL1
Sources

Drugs & Therapeutics for Retinal Vein Occlusion

About this section

Drugs for Retinal Vein Occlusion (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 146)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bevacizumab Approved, Investigational Phase 4 216974-75-3
2
Dipivefrin Approved Phase 4 52365-63-6 3105
3
Nepafenac Approved, Investigational Phase 4 78281-72-8 151075
4
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
5 Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
6
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
7
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
8
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
9
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
10
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
11
Ranibizumab Approved Phase 4 347396-82-1 459903
12
Lactitol Approved, Investigational Phase 4 585-86-4 157355
13
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
14 Antineoplastic Agents, Immunological Phase 4
15 Dexamethasone 21-phosphate Phase 4
16 HIV Protease Inhibitors Phase 4
17
protease inhibitors Phase 4
18 Analgesics, Non-Narcotic Phase 4
19 Anti-Inflammatory Agents, Non-Steroidal Phase 4
20 Analgesics Phase 4
21 Antirheumatic Agents Phase 4
22 Cathartics Phase 4
23 Lubricant Eye Drops Phase 4
24 Laxatives Phase 4
25 Carboxymethylcellulose Sodium Phase 4
26 Protective Agents Phase 4
27 Mitogens Phase 4
28 Endothelial Growth Factors Phase 4
29 Neuroprotective Agents Phase 4
30 Methylprednisolone Acetate Phase 4
31 Angiogenesis Inhibitors Phase 4
32 Gastrointestinal Agents Phase 4
33 Anti-Inflammatory Agents Phase 4
34 Hormone Antagonists Phase 4
35 glucocorticoids Phase 4
36 Hormones Phase 4
37 Antineoplastic Agents, Hormonal Phase 4
38 Antiemetics Phase 4
39 BB 1101 Phase 4
40
Histidine Investigational, Nutraceutical Phase 4 71-00-1 6274
41
Atorvastatin Approved Phase 3 134523-00-5 60823
42
Betamethasone Approved, Vet_approved Phase 2, Phase 3 378-44-9 9782
43
Povidone-iodine Approved Phase 3 25655-41-8
44
Iodine Approved, Investigational Phase 3 7553-56-2 807
45
Povidone Approved Phase 3 9003-39-8 131751496
46
Benzocaine Approved, Investigational Phase 3 1994-09-7, 94-09-7 2337
47
tannic acid Approved Phase 3 1401-55-4
48
Triamcinolone Approved, Vet_approved Phase 3 124-94-7 31307
49
Aspirin Approved, Vet_approved Phase 3 50-78-2 2244
50
Heparin Approved, Investigational Phase 3 9005-49-6 772 9812414

Interventional clinical trials:

(show top 50) (show all 245)
# Name Status NCT ID Phase Drugs
1 Evaluation of the "Treat-and-extend" Scheme in Patients With Retinal Vein Occlusion (RVO) With and Without LASER Treatment of Ischaemic Retinal Areas Unknown status NCT02522897 Phase 4 Ranibizumab
2 Phase 4 Study of Intravitreal Aflibercept Injection for Recalcitrant Central Retinal Vein Occlusion Associated Macular Edema Despite Prior Anti-Vascular Endothelial Growth Factor (VEGF) Therapy. (ARChiMEDES) Unknown status NCT01857544 Phase 4 Aflibercept
3 Retinal Sensitivity in Branch Retinal Vein Occlusion After Anti-VEGF Therapy Unknown status NCT02527733 Phase 4 Ranibizumab;Ranibizumab and laser
4 Prospective Trial of Treat and Extend Aflibercept for Macular Edema Secondary to Branch Retinal Vein Occlusion: the PLATON Trial Unknown status NCT03405376 Phase 4 Intravitreal aflibercept injection
5 Combined Treatment of Intravitreous Bevacizumab and Triamcinolone for the Treatment or Macular Edema Secondary to Central Retinal Vein Occlusion Unknown status NCT00566761 Phase 4 bevacizumab and triamcinolone
6 Ozurdex Versus Ranibizumab Versus Combination for Central Retinal Vein Unknown status NCT01827722 Phase 4 Ozurdex;Ranibizumab;Combination Ozurdex with Ranibizumab PRN
7 A Phase IV Open Label Trial of the Safety, Tolerability and Efficacy of 0.5mg Ranibizumab Intravitreal Injections Combined With Wide Field Angiography Guided Panretinal Photocoagulation vs. 0.5mg Ranibizumab Intravitreal Injection Monotherapy in Subjects With Ischemic Central Retinal Vein Occlusion, Hemi Retinal Vein Occlusion, and Branch Retinal Vein Occlusion Who Incompletely Respond to at Least 2 Consecutive Intravitreal Injections in the Past 4 Months. Completed NCT01710839 Phase 4 0.5mg Ranibizumab
8 An Open-label, Multi-center, 6-month Extension Study Comparing the Long-term Efficacy and Safety of Lucentis (Ranibizumab) Intravitreal Injections Versus Ozurdex (Dexamethasone) Intravitreal Implant in Patients With Visual Impairment Due to Macular Edema Following Branch Retinal Vein Occlusion (BRVO) or Central Retinal Vein Occlusion (CRVO) Who Have Completed the Respective Core Study (CRFB002EDE17 or CRFB002EDE18) Completed NCT01580020 Phase 4 Dexamethasone
9 Pilot Study on Efficacy and Tolerance of Intravitreous Injection of Ranibizumab (Lucentis®) in Early-onset Central Retinal Vein Occlusion in Comparison to Hemodilution Using Erythrocytapheresis Completed NCT01448018 Phase 4 ranibizumab
10 Chilean Interventional Open Label Pilot Study, to Assess the Efficacy and Safety of Lucentis® (Ranibizumab Intravitreal Injections) in Patients With Visual Impairment Due to Diabetic Macular Edema. Completed NCT02140411 Phase 4 Ranibizumab Intravitreal injections
11 Safety and Efficacy Study of Ozurdex® Compared to Lucentis® in Patients With Branch Retinal Vein Occlusion Completed NCT01427751 Phase 4 dexamethasone intravitreal implant
12 Response of Retinal Vessels to Anti Vascular Endothelial Growth Factor (VEGF) Treatment in Patients With Branch Retinal Vein Occlusion (BRVO) Completed NCT01027481 Phase 4 Lucentis
13 A Multi-center, Single-arm, Interventional Phase 4 Study to Evaluate a Treat and Extend Regimen of Intravitreal Aflibercept for Treatment of Macular Edema Secondary to Central Retinal Vein Occlusion Completed NCT02800642 Phase 4 Aflibercept (Eylea, BAY86-5321)
14 Open Label Macugen for the Treatment of Macular Edema Secondary to Branch Retinal Vein Occlusion Completed NCT00406107 Phase 4 pegaptanib sodium (Macugen)
15 Twelve Months Experience With a Dexamethasone-implant for the Treatment of Macular Edema Associated With Retinal Vein Occlusion Completed NCT01767545 Phase 4 Dexamethasone implant;Bevacizumab
16 Peripheral and Macular Retinal Vascular Perfusion and Leakage Dynamics in Diabetic Macular Edema and Retinal Venous Occlusions During Intravitreal Aflibercept Injection (IAI) Treatment for Retinal Edema: PERMEATE Study Completed NCT02503540 Phase 4 Aflibercept
17 Randomized Trial Comparing Injection Frequency Between Aflibercept and Ranibizumab in Patients With Central Retinal Vein Occlusion With a Treat and Extend Algorithm Completed NCT02274259 Phase 4 Aflibercept;Ranibizumab
18 A 12-month, Phase IV, Open-label, Randomized, Active Controlled, 2-arm, Multicenter Study Assessing the Efficacy and Safety of Intravitreal Ranibizumab Combined With Grid&Direct Short Pulse Laser Photocoagulation Versus a PRN Ranibizumab Monotherapy in Japanese Patients With Macular Edema Secondary to Branch Retinal Vein Occlusion (BRVO) Completed NCT02953938 Phase 4
19 Evaluation of Visual Acuity Improvement of a PRN Regimen Using Ranibizumab for Macular Edema Due to Ischemic and Non- Ischemic Branch Retinal Vein Occlusion. Completed NCT02478515 Phase 4 Ranibizumab
20 NEWTON: A Single-center Open Label Study Evaluating Intravitreal Aflibercept Injection (IAI) for Previously Treated Macular Edema Associated With Central Retinal Vein Occlusions Completed NCT01870427 Phase 4 Aflibercept (2.0 mg)
21 A 6-Month, Single Site, Masked, Randomized,Controlled Study to Assess Efficacy of Osurdex as Adjunct to Avastin Compared With Avastin Alone in the Treatment of Patients With Macular Edema Due to Central or Branch Retinal Vein Occlusion Completed NCT01085734 Phase 4 Avastin;Osurdex;Avastin
22 A Multicenter Randomized Study Evaluating Dosing Regimens for Treatment With Intravitreal Ranibizumab Injections in Subjects With Macular Edema Following Retinal Vein Occlusion Completed NCT01277302 Phase 4 Ranibizumab
23 A Phase IV, Open Label, Multi-center Study to Assess the Effect of Intravitreal Injections of Macugen (Pegaptanib Sodium Injection) Administered Every 6 Weeks for 48 Weeks on the Corneal Endothelium. Completed NCT01573572 Phase 4 pegaptanib sodium injection
24 A Safety and Efficacy Study of OZURDEX® in Macular Edema Associated With Branch Retinal Vein Occlusion Completed NCT01903720 Phase 4 dexamethasone implant
25 Morphological and Functional Retinal Changes Following Retinal Photocoagulation Using a Semiautomated Patterned Scanning Laser System in Proliferative Retinopathy or Macular Edema Secondary to Diabetes Mellitus or Retinal Vein Occlusion Completed NCT00682240 Phase 4
26 The RAVE (Rubeosis Anit-VEgf) Trial, Utilizes Monthly Intravitreal Bevazizumab (Avastin) Injections for 12 Months to See if Total VEGF Blockade Will Prevent Neovascular Glaucoma and Eliminate the Need for Panretinal Photocoagulation in Patients With Ischemic Central Retinal Vein Occlusion Completed NCT00557232 Phase 4 bevacizumab
27 Cytokine and Visual Outcome Variations in Eyes Receiving a Variable Dosing Ranibizumab Treatment: The COVERT Study Recruiting NCT03056092 Phase 4 Intravitreal ranibizumab
28 Cytokine and Visual Outcome Variations in Eyes Receiving a Variable Dosing Aflibercept Treatment: The COVARIANT Study Recruiting NCT03056079 Phase 4 Intravitreal aflibercept
29 Bevacizumab Versus DEX Implant Followed by Bevacizumab in ME Secondary to BRVO Recruiting NCT03892434 Phase 4 Intravitreal bevacizumab and dexamethasone implant Injection
30 A Randomized Trial Comparing Treatment With Aflibercept and Ranibizuamab for Macular Edema After Branch Retinal Vein Occlusion Recruiting NCT03709745 Phase 4 Aflibercept Injection [Eylea];Ranibizumab Injection [Lucentis]
31 A 12-month, Open-label, Multicenter, Phase 4 Study to Evaluate the Efficacy and Safety of OZURDEX® Implant 700 µg (Dexamethasone) on Patients With Macular Edema Secondary to Retinal Vein Occlusion in China (YANGTZE Study) Active, not recruiting NCT03908307 Phase 4 OZURDEX
32 Pain Control Following Intravitreal Injection Using Topical Nepefanac 0.3% or Pressure Patching: A Prospective, Randomized, Placebo Controlled Trial Enrolling by invitation NCT03918590 Phase 4 nepafenac 0.3% suspension (Ilevro; Alcon, Fort Worth, TX);Theratears tear drop, (Akron, Ann 111 Arbor, MI)
33 Different Regimens of Ranibizumab Treatment for Macular Edema Secondary to Retinal Vein Occlusion: a Randomized and Controlled Clinical Study. Not yet recruiting NCT04062370 Phase 4 Ranibizumab
34 Correlation of Vascular Endothelial Growth Factor Levels in Anterior Chamber Fluid to Disease State in Patients With Retinal Vein Occlusion Receiving Standard of Care Treatment Not yet recruiting NCT04707625 Phase 4 Aflibercept Ophthalmic
35 Effect on Pain and Inflammation With DEXTENZA Treatment in Patients Undergoing Intravitreal Anti-VEGF Injections Not yet recruiting NCT04563299 Phase 4 Dextenza 0.4Mg Ophthalmic Insert;Prednisolone Acetate
36 Phase 4 Study of Ranibizumab for the Treatment of Visual Impairment Due to Macular Edema Secondary to Branch Retinal Vein Occlusion in Patients With Initial Fair Visual Acuity Terminated NCT01795209 Phase 4 Ranibizumab
37 Combination OZURDEX® & LUCENTIS® vs. OZURDEX® Monotherapy in Incomplete-Responders With Diabetic Macular Edema: The COLLIDE Trial Terminated NCT02684084 Phase 4 Ozurdex;Lucentis
38 A Randomized Trial Comparing Intravitreal Ranibizumab and Macular Laser Photocoagulation for the Treatment of Macular Edema Following Branch Retinal Vein Occlusion Unknown status NCT01189526 Phase 3 Ranibizumab
39 Comparing the Effectiveness and Costs of Bevacizumab to Ranibizumab in Patients With Retinal Vein Occlusions (The BRVO Study) Unknown status NCT01635803 Phase 2, Phase 3 Bevacizumab;Ranibizumab
40 Combined Intravitreal Injection of Bevacizumab and Fasudil Versus Bevacizumab Alone for Macular Edema Secondary to Retinal Vein Occlusion in Previously Treated Patients. Unknown status NCT03391219 Phase 2, Phase 3 injection bevacizumab;injection Combined Bevacizumab and Fasudil
41 Atorvastatin Toronto Retinal Vein Occlusion Study (ATORVO) Unknown status NCT00517257 Phase 3 Atorvastatin;Placebo
42 Multi-center, Randomized, Double-masked, Placebo-controlled Phase III Clinical Study of Conbercept Ophthalmic Injection for Patients With BRVO. Unknown status NCT03108352 Phase 3 Conbercept ophthalmic injection
43 Prospective, Randomised, Placebo-controlled, Double-masked, Three-armed Multi-centre Trial of Aganirsen Versus Vehicle in Patients After Ischaemic Central Retinal Vein Occlusion With a High Risk to Develop Neovascular Glaucoma Unknown status NCT02947867 Phase 2, Phase 3 aganirsen
44 Comparison of Therapeutic Effects Between Intravitreal Injection of Bevacizumab With Intravitreal Injection of Bevacizumab and Targeted Laser Photocoagulation of Non Perfused Areas of Retina in Patients With Acute Retinal Vein Occlusion Unknown status NCT03353324 Phase 2, Phase 3 intravitreal injection of bevacizumab
45 An Efficacy and Safety Trial of Intravitreal Injection of Conbercept Ophthalmic Injection in Treatment of Macular Edema Secondary to Central Retinal Vein Occlusion Unknown status NCT03223714 Phase 3 Conbercept Ophthalmic Injection;sham injection
46 A Randomized Double-masked, Phase III Study Assessing Ranibizumab Intravitreal Injections Versus Sham Control in Patients With Visual Impairment Due to Macular Edema (ME) Secondary to Branch Retinal Vein Occlusion (BRVO) [Blossom] Completed NCT01976338 Phase 3 Ranibizumab 0.5 mg
47 A 3-month, Phase III, Open-label, Single Arm, Multicenter Study Assessing the Efficacy and Safety of 0.5 mg Ranibizumab Monthly Intravitreal Injections as Monotherapy in Patients With Visual Impairment Due to Macular Edema Secondary to Branch or Central Retinal Vein Occlusion (RVO) Completed NCT01377597 Phase 3 ranibizumab
48 Extended Follow-up of Patients With Macular Edema Due to bRanch rETinal Vein Occlusion (BRVO) or centrAl Retinal veIn occlusioN (CRVO) Previously Treated With Intravitreal Ranibizumab Completed NCT01198327 Phase 3 ranibizumab
49 A Randomized Study Comparing the Safty Anf Efficacy of Ranibizumab (Lucentis®) to Sham in Patients With Macular Edema Secondary to Central Retinal Vein Occlusion (CRVO Completed NCT00567697 Phase 3 ranibizumab;ranibizumab
50 A Randomized Double-masked, Phase III Study Assessing Ranibizumab Intravitreal Injections Versus Sham Control in Patients With Visual Impairment Due to Macular Edema (ME) Secondary to Central Retinal Vein Occlusion (CRVO) [Camellia] Completed NCT01976312 Phase 3 Ranibizumab 0.5 mg

Search NIH Clinical Center for Retinal Vein Occlusion

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Retinal Vein Occlusion cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Retinal Vein Occlusion:
Bone marrow-derived hematopoietic stem cells for retinopathy
Embryonic/Adult Cultured Cells Related to Retinal Vein Occlusion:
Bone marrow-derived hematopoietic stem cells (family) PMIDs: 22247454
Bone marrow-derived hematopoietic CD34+ progenitors PMIDs: 22247454

Cochrane evidence based reviews: retinal vein occlusion

Sources

Genetic Tests for Retinal Vein Occlusion

About this section
Sources

Anatomical Context for Retinal Vein Occlusion

About this section

MalaCards organs/tissues related to Retinal Vein Occlusion:

40
Endothelial, Eye, Retina, Bone Marrow, Myeloid, Neutrophil, Bone
Sources

Publications for Retinal Vein Occlusion

About this section

Articles related to Retinal Vein Occlusion:

(show top 50) (show all 4744)
# Title Authors PMID Year
1
Visual acuity and foveal thickness after vitrectomy for macular edema associated with branch retinal vein occlusion: a case series. 54 61
20429890 2010
2
Aqueous vascular endothelial growth factor levels are associated with serous macular detachment secondary to branch retinal vein occlusion. 54 61
19881397 2010
3
Association of retinal sensitivity and morphology during antiangiogenic treatment of retinal vein occlusion over one year. 61 54
19744723 2009
4
The anti-angiogenic isoforms of VEGF in health and disease. 61 54
19909248 2009
5
[Retinal vein occlusion: anti-VEGF treatments]. 54 61
19879018 2009
6
Changes of aqueous vascular endothelial growth factor and pigment epithelium-derived factor following intravitreal bevacizumab for macular oedema secondary to branch retinal vein occlusion. 61 54
19624346 2009
7
Changes in foveal thickness after vitrectomy for macular edema with branch retinal vein occlusion and intravitreal vascular endothelial growth factor. 61 54
18797821 2009
8
Anti-vascular endothelial growth factor therapy for neovascular ocular diseases other than age-related macular degeneration. 61 54
19381089 2009
9
Changes of aqueous vascular endothelial growth factor and interleukin-6 after intravitreal triamcinolone for branch retinal vein occlusion. 54 61
19278477 2008
10
Changes of vascular endothelial growth factor after vitrectomy for macular edema secondary to retinal vein occlusion. 61 54
18988180 2008
11
Visual prognosis and vitreous cytokine levels after arteriovenous sheathotomy in branch retinal vein occlusion associated with macular oedema. 54 61
18039346 2008
12
Retinal vascular occlusions: an interdisciplinary challenge. 54 61
19626196 2008
13
The prevalence of activated protein C (APC) resistance and factor V Leiden is significantly higher in patients with retinal vein occlusion without general risk factors. Case-control study and meta-analysis. 54 61
18449423 2008
14
Ranibizumab for macular edema due to retinal vein occlusions: implication of VEGF as a critical stimulator. 61 54
18362932 2008
15
Aqueous humour levels of cytokines are correlated to vitreous levels and severity of macular oedema in branch retinal vein occlusion. 61 54
16826241 2008
16
Anticoagulant therapy after retinal vein occlusion in patients with protein S deficiency (Protein S deficiency with homozygous factor V Leiden mutation in central retinal vein occlusion. Vol. 42[4]). 54 61
18059510 2007
17
Thrombophilic mutations and risk of retinal vein occlusion. 61 54
18235909 2007
18
[Bevacizumab for the treatment of macular edema secondary to retinal vein occlusion]. 61 54
17372737 2007
19
The deficiencies of protein C, protein S and antithrombin III in patients with retinal vein occlusion: a Turkish sample. 54 61
17105492 2006
20
Retinal vein occlusion associated with antithrombin deficiency secondary to a novel G9840C missense mutation. 54 61
16908819 2006
21
Recurrent branch retinal vein occlusion with factor V leiden mutation. 54 61
16113634 2006
22
[Bevacizumab for treatment of macular edema secondary to retinal vein occlusion]. 61 54
16763863 2006
23
Intravitreal levels of vascular endothelial growth factor and interleukin-6 are correlated with macular edema in branch retinal vein occlusion. 54 61
16133018 2006
24
[Recurrent incomplete central retinal vein occlusion in a patient with hereditary thrombophilia]. 61 54
16848214 2006
25
Antiphospholipid syndrome in patients with retinal venous occlusion. 54 61
16461072 2006
26
Pathogenesis of macular edema with branch retinal vein occlusion and intraocular levels of vascular endothelial growth factor and interleukin-6. 61 54
16086947 2005
27
Increased prevalence of factor V Leiden in patients with retinal vein occlusion and under 60 years of age. 61 54
16113792 2005
28
Inhibition of ocular angiogenesis by an adenovirus carrying the human von Hippel-Lindau tumor-suppressor gene in vivo. 54 61
15111579 2004
29
Elevated erythropoietin in vitreous with ischemic retinal diseases. 61 54
15073535 2004
30
MTHFR C677T mutation, factor II G20210A mutation and factor V Leiden as risks factor for youth retinal vein occlusion. 54 61
14994919 2003
31
Hyperhomocysteinemia in central retinal vein occlusion in young adults. 54 61
15513477 2003
32
Anticardiolipin antibodies in patients with retinal vein occlusion and no risk factors: a prospective study. 61 54
12972759 2003
33
Genetic determinants of fasting and post-methionine hyperhomocysteinemia in patients with retinal vein occlusion. 61 54
12877902 2003
34
High prevalence of resistance to APC in young patients with retinal vein occlusion. 61 54
11935272 2002
35
Retinal vein occlusion and factor V Leiden and prothrombin 20210 G:A mutations. 61 54
11820306 2001
36
No excess of factor V:Q506 genotype but high prevalence of anticardiolipin antibodies without antiendothelial cell antibodies in retinal vein occlusion in young patients. 61 54
11340395 2001
37
Protein C, protein S and antithrombin III deficiencies in retinal vein occlusion. 54 61
10634552 1999
38
Prevalence of factor V Leiden in patients with retinal vein occlusion. 61 54
10634553 1999
39
Factor V Leiden and prothrombin 20210 A mutations in patients with central and branch retinal vein occlusion. 54 61
10634550 1999
40
Retinal vein occlusion associated with methylenetetrahydrofolate reductase mutation. 54 61
10485556 1999
41
Diagnosis of activated protein C resistance in retinal vein occlusion. 61 54
9924393 1998
42
Bilateral retinal vein occlusion associated with factor V Leiden mutation. 61 54
9730185 1998
43
Factor V Leiden, activated protein C resistance, and retinal vein occlusion. 61 54
9730172 1998
44
Bilateral retinal vein occlusion associated with 5,10-methylenetetrahydrofolate reductase mutation. 61 54
9402832 1997
45
Prevalence of factor V Leiden in young adults with retinal vein occlusion. 61 54
9031476 1997
46
Activated protein C and retinal vein occlusion. 54 61
8703852 1996
47
Hypoxia-induced expression of vascular endothelial growth factor by retinal cells is a common factor in neovascularizing ocular diseases. 54 61
7540233 1995
48
[Retinal vein occlusion and resistance to activated protein C]. 54 61
8745708 1995
49
Normal activities of protein C, protein S and antithrombin III in young patients with retinal vein occlusion. 61 54
2151449 1990
50
Neovascular glaucoma - A review. 61
33595466 2021
Sources

Variations for Retinal Vein Occlusion

About this section
Sources

Expression for Retinal Vein Occlusion

About this section
Search GEO for disease gene expression data for Retinal Vein Occlusion.
Sources

Pathways for Retinal Vein Occlusion

About this section

Pathways related to Retinal Vein Occlusion according to GeneCards Suite gene sharing:

(show top 50) (show all 63)
# Super pathways Score Top Affiliating Genes
1
ERK Signaling 63
Show member pathways
 13.86 VEGFA TNF KDR IL6 IL1B CXCL8
2
PEDF Induced Signaling 63
Show member pathways
 13.68 TNF SERPINF1 KDR IL6 IL1B F2
3
TGF-Beta Pathway 63
Show member pathways
 13.57 VEGFA TNF KDR IL6 IL1B F2
4
Akt Signaling 63
Show member pathways
 13.46 TNF KDR IL6 IL1B CXCL8 CXCL12
5
Response to elevated platelet cytosolic Ca2+ 65
Show member pathways
 13.36 VEGFA SERPINE1 SERPINC1 F5 F3 F2
6
PAK Pathway 63
Show member pathways
 13.34 TNF KDR IL6 IL1B CXCL8 CXCL12
7
Toll-like Receptor Signaling Pathway 36 1
Show member pathways
 13.1 TNF SERPINE1 IL6 IL1B CXCL8 CCL2
8
p70S6K Signaling 63
Show member pathways
 13.08 KDR IL6 F2 CXCL12 CCL2 ACE
9
Allograft rejection 36 1
Show member pathways
 12.91 VEGFA TNF IL6 IL1B CXCL8 CXCL12
10
Human cytomegalovirus infection 36
Show member pathways
 12.91 VEGFA TNF IL6 IL1B CXCL8 CXCL12
11
Pathways in cancer 36
12.9 VEGFA IL6 F2 EDN1 CXCL8 CXCL12
12
MAPK signaling pathway 36 1
12.79 VEGFA TNF KDR IL1B ANGPT2
13
Salmonella infection (KEGG) 36
Show member pathways
 12.77 TNF IL6 IL1B F2 CXCL8
14
NF-KappaB Family Pathway 63
Show member pathways
 12.74 TNF KDR IL6 IL1B CXCL12
15
Toll-Like receptor Signaling Pathways 64
Show member pathways
 12.73 TNF SERPINE1 IL6 IL1B F3 EDN1
16
Immune response IL-23 signaling pathway 23
Show member pathways
 12.63 TNF IL6 IL1B F2 CCL2 ANGPT2
17
IL-17 Family Signaling Pathways 64
Show member pathways
 12.39 TNF IL6 IL1B CXCL8 CCL2
18
Chemokine Superfamily Pathway: Human/Mouse Ligand-Receptor Interactions 64
Show member pathways
 12.39 TNF IL6 CXCL8 CXCL12 CCL2
19
Immune response IFN alpha/beta signaling pathway 23
Show member pathways
 12.31 TNF KDR IL6 IL1B CXCL8 CXCL12
20
Dilated cardiomyopathy 36
Show member pathways
 12.29 TNF IL6 EDN1 ACE
21
NOD-like receptor signaling pathway 36
12.29 TNF IL6 IL1B CXCL8 CCL2
22
Bacterial infections in CF airways 23
Show member pathways
 12.23 TNF IL6 IL1B CXCL8
23
Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways 1
12.22 VEGFA TNF IL6 IL1B CXCL8
24
Formation of Fibrin Clot (Clotting Cascade) 65
Show member pathways
 12.2 SERPINE1 SERPINC1 F5 F3 F2
25
Complement and coagulation cascades 36 1
12.14 SERPINE1 SERPINC1 F5 F3 F2
26
Folate Metabolism 1
Show member pathways
 12.13 TNF SERPINE1 MTHFR IL6 IL1B F2
27
Yersinia infection 36
12.11 TNF IL6 IL1B CXCL8 CCL2
28
Fluid shear stress and atherosclerosis 36
12.05 VEGFA TNF KDR IL1B EDN1 CCL2
29
Spinal Cord Injury 1
12.04 TNF IL6 IL1B CXCL8 CCL2
30
Senescence and Autophagy in Cancer 1
12.01 SERPINE1 IL6 IL1B CXCL8
31
NF-kappa B signaling pathway 36
12 TNF IL1B CXCL8 CXCL12
32
TNF signaling pathway 36
12 TNF IL6 IL1B EDN1 CCL2
33
Amoebiasis 36
11.98 TNF IL6 IL1B CXCL8
34
HIF-1 signaling pathway 36
11.96 VEGFA SERPINE1 IL6 EDN1 ANGPT2
35
Angiogenesis (CST) 4
11.91 KDR F3 CCL2 ANGPT2
36
Interleukin-4 and 13 signaling 65
11.86 VEGFA TNF IL6 IL1B CXCL8 CCL2
37
Pertussis 36
11.83 TNF IL6 IL1B CXCL8
38
Th1 Differentiation Pathway 64
Show member pathways
 11.79 TNF IL6 IL1B
39
Dendritic Cells Developmental Lineage Pathway 64
11.77 TNF IL6 IL1B
40
HIF-1-alpha transcription factor network 1
11.74 VEGFA SERPINE1 EDN1 CXCL12
41
Legionellosis 36
11.65 TNF IL6 IL1B CXCL8
42
Photodynamic therapy-induced NF-kB survival signaling 1
Show member pathways
 11.65 VEGFA TNF IL6 IL1B CXCL8
43
Hepatitis C and Hepatocellular Carcinoma 1
11.6 VEGFA IL6 CXCL8
44
MSP-RON Signaling 63
11.57 TNF IL1B CCL2
45
Transcription_Role of VDR in regulation of genes involved in osteoporosis 23
11.54 TNF IL6 IL1B
46
Malaria 36
11.5 TNF IL6 IL1B CXCL8 CCL2
47
Rheumatoid arthritis 36
11.47 VEGFA TNF IL6 IL1B CXCL8 CXCL12
48
Interleukin-10 signaling 65
11.46 TNF IL6 IL1B CXCL8 CCL2
49
African trypanosomiasis 36
11.45 TNF IL6 IL1B
50
Lung fibrosis 1
11.43 TNF IL6 IL1B EDN1 CXCL8 CCL2
Sources

GO Terms for Retinal Vein Occlusion

About this section

Cellular components related to Retinal Vein Occlusion according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.91 VEGFA TNF SERPINF1 SERPINE1 SERPINC1 LOXL1
2 collagen-containing extracellular matrix GO:0062023 9.81 SERPINF1 SERPINE1 SERPINC1 LOXL1 F3 F2
3 extracellular region GO:0005576 9.6 VEGFA TNF SERPINF1 SERPINE1 SERPINC1 LOXL1
4 platelet alpha granule lumen GO:0031093 9.43 VEGFA SERPINE1 F5

Biological processes related to Retinal Vein Occlusion according to GeneCards Suite gene sharing:

(show top 50) (show all 64)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 10.11 VEGFA TNF IL6 IL1B F3 CXCL8
2 immune response GO:0006955 10.1 TNF IL6 IL1B CXCL8 CXCL12 CCL2
3 inflammatory response GO:0006954 10.09 TNF IL6 IL1B CXCL8 CCL2
4 positive regulation of cell proliferation GO:0008284 10.08 VEGFA KDR IL6 IL1B F2 EDN1
5 cellular protein metabolic process GO:0044267 10.03 SERPINC1 IL6 F5 F2
6 positive regulation of ERK1 and ERK2 cascade GO:0070374 10.01 VEGFA TNF KDR CCL2
7 blood coagulation GO:0007596 10 SERPINC1 F5 F3 F2
8 positive regulation of protein phosphorylation GO:0001934 10 VEGFA TNF KDR IL1B F2
9 regulation of cell shape GO:0008360 9.97 VEGFA KDR F2 CCL2
10 response to hypoxia GO:0001666 9.97 VEGFA MTHFR EDN1 CXCL12 ANGPT2
11 platelet degranulation GO:0002576 9.95 VEGFA SERPINE1 F5 APOH
12 positive regulation of DNA-binding transcription factor activity GO:0051091 9.93 TNF IL6 IL1B EDN1
13 positive regulation of cell migration GO:0030335 9.93 VEGFA KDR IL1B F3 EDN1 CXCL12
14 neutrophil chemotaxis GO:0030593 9.91 EDN1 CXCL8 CCL2
15 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.91 VEGFA TNF KDR F2
16 angiogenesis GO:0001525 9.91 VEGFA SERPINE1 KDR CXCL8 CCL2 ANGPT2
17 regulation of insulin secretion GO:0050796 9.9 TNF IL6 IL1B
18 chemokine-mediated signaling pathway GO:0070098 9.9 CXCL8 CXCL12 CCL2
19 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.9 VEGFA TNF IL6
20 cellular response to organic cyclic compound GO:0071407 9.89 TNF IL1B CCL2
21 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.89 TNF IL1B EDN1
22 positive regulation of endothelial cell proliferation GO:0001938 9.89 VEGFA KDR F3 CXCL12
23 positive regulation of endothelial cell migration GO:0010595 9.88 VEGFA KDR EDN1
24 positive regulation of smooth muscle cell proliferation GO:0048661 9.88 TNF IL6 EDN1
25 positive regulation of MAP kinase activity GO:0043406 9.87 VEGFA TNF EDN1
26 humoral immune response GO:0006959 9.87 TNF IL6 CCL2
27 positive regulation of cell adhesion GO:0045785 9.86 VEGFA TNF CXCL12
28 response to activity GO:0014823 9.86 IL6 EDN1 ANGPT2
29 positive regulation of nitric oxide biosynthetic process GO:0045429 9.85 TNF IL1B EDN1
30 positive regulation of JAK-STAT cascade GO:0046427 9.83 TNF IL6 F2
31 lipopolysaccharide-mediated signaling pathway GO:0031663 9.83 TNF IL1B CCL2
32 branching involved in blood vessel morphogenesis GO:0001569 9.82 VEGFA KDR EDN1
33 hemostasis GO:0007599 9.8 SERPINC1 F5 F3 F2
34 cellular response to lipopolysaccharide GO:0071222 9.8 TNF SERPINE1 IL6 IL1B CXCL8 CCL2
35 negative regulation of gene expression GO:0010629 9.8 VEGFA TNF SERPINF1 KDR EDN1 CXCL8
36 negative regulation of neurogenesis GO:0050768 9.79 TNF IL6 IL1B
37 positive regulation of glial cell proliferation GO:0060252 9.77 TNF IL6 IL1B
38 induction of positive chemotaxis GO:0050930 9.76 VEGFA CXCL8 CXCL12
39 positive regulation of blood coagulation GO:0030194 9.75 SERPINE1 F2 APOH
40 regulation of establishment of endothelial barrier GO:1903140 9.73 TNF IL1B
41 neutrophil mediated immunity GO:0002446 9.73 IL6 ACE
42 negative regulation of blood coagulation GO:0030195 9.73 SERPINE1 EDN1 APOH
43 negative regulation of vascular wound healing GO:0061044 9.72 TNF SERPINE1
44 negative regulation of smooth muscle cell apoptotic process GO:0034392 9.72 EDN1 APOH
45 positive regulation of prostaglandin secretion GO:0032308 9.72 IL1B EDN1
46 negative regulation of lipid storage GO:0010888 9.72 TNF IL6
47 regulation of blood coagulation GO:0030193 9.72 SERPINC1 F2 APOH
48 vascular wound healing GO:0061042 9.71 VEGFA KDR
49 protein kinase B signaling GO:0043491 9.71 TNF KDR IL1B CCL2
50 positive regulation of axon extension involved in axon guidance GO:0048842 9.7 VEGFA CXCL12

Molecular functions related to Retinal Vein Occlusion according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 heparin binding GO:0008201 9.62 VEGFA SERPINC1 F2 APOH
2 growth factor activity GO:0008083 9.56 VEGFA IL6 F2 CXCL12
3 chemokine activity GO:0008009 9.54 CXCL8 CXCL12 CCL2
4 protease binding GO:0002020 9.46 TNF SERPINE1 SERPINC1 F3
5 signaling receptor binding GO:0005102 9.43 SERPINE1 F2 EDN1 CXCL12 CCL2 ANGPT2
6 cytokine activity GO:0005125 9.23 VEGFA TNF IL6 IL1B EDN1 CXCL8
Sources

Sources for Retinal Vein Occlusion

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....